ICCM - Why Is Breast Cancer Diagnostic Focused IceCure Medical Stock Trading Higher Today? | Benzinga
IceCure Medical Ltd (NASDAQ: ICCM) announced that new data was presented at the European Society of Breast Imaging Scientific Meeting, validating IceCure's ProSense Cryoablation is a safe and effective outpatient procedure for breast cancer with a 96.8% success rate.
The study used ProSense for cryoablation treatment of 31 patients with early-stage breast cancer who declined surgery, the standard of care.
ProSense System is a ...